EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase IV)Kohortenstudie

Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study

M Blauwblomme, A-S Viskens, E Bonne, E Borgers, C Cox, G De Vos, L Derycke, A-S Eeckels, S Halewyck, V Hox, P Janssen, P Janssen und 12 weitere

Rhinology Journal · 01.04.2026 · 0-0

DOI: 10.4193/rhin26.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Rhinology Journal, online erschienen am 01.04.2026. Verfasst von M Blauwblomme und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium;Upper Airways Research Laboratory, Department of Head and Skin, Ghent Un…. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Antibodies, Monoclonal, Humanized, Omalizumab.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monoclonal antibody therapies targeting type 2 inflammation for chronic rhinosinusitis with nasal polyps (CRSwNP) have shown efficacy in randomized controlled trials (RCTs), however prospective real-world comparative data across all appro-ved biologics remain limited. We aimed to evaluate the real-world effectiveness of omalizumab, mepolizumab, and dupilumab in patients with severe CRSwNP. Methodology: A prospective, multicentre, real-world phase IV study in Belgium, enrolling 360 patients with severe CRSwNP initiating treatment with omalizumab (n=65), mepolizumab (n=242), or dupilumab (n=53) between March 2022 and April 2025. Clinical data were collected at baseline and after 6 months. The therapeutic response was evaluated based on EUFOREA criteria.

Results

After 6 months, nasal polyp score (NPS), olfactory function, and patient-reported outcomes improved across all biologics, with concurrent improvements in asthma control within each treatment group. A good-to-excellent multidomain therapeutic response was achieved in 51% of patients, and treatment continuation beyond 6 months was observed in 74% of omalizumab-, 81% of mepolizumab-, and 92% of dupilumab-treated patients. No severe adverse events were reported.

Conclusion

In this real-world cohort, the three registered biologics provided significant clinical benefit in severe CRSwNP, with numerically larger improvements observed in patients treated with dupilumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsAntibodies, Monoclonal, HumanizedOmalizumabBiological ProductsSinusitisRhinitisHumansFemaleChronic DiseaseProspective StudiesMaleMiddle AgedTreatment OutcomeAdultBelgium

Substanzen

Antibodies, Monoclonal, HumanizedOmalizumabmepolizumabdupilumabBiological Products

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium;Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
  • KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Unit, Leuven, Belgium;Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;Depar…
  • Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Leuven, Belgium.
  • Department of Otorhinolaryngology, Jessa Hospital, Hasselt, Belgium.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Sint-Lucas Hospital, Ghent, Belgium.

Zitieren

APA

Blauwblomme, M., Viskens, A. S., Bonne, E., Borgers, E., Cox, C., De Vos, G., Derycke, L., Eeckels, A. S., Halewyck, S., Hox, V., Janssen, P., Janssen, P., Lemmens, W., Rogister, F., Speleman, K., Syssauw, M., Vanderveken, O., Vandewalle, E., Vanhee, S., …, & Hellings, P. W. (2026). Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin26.004

Vancouver

Blauwblomme M, Viskens AS, Bonne E, Borgers E, Cox C, De Vos G, et al. Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study. Rhinology Journal. 2026;0(0):0-0. doi:10.4193/rhin26.004

BibTeX
@article{Blauwblomme2026,
  author = {Blauwblomme, M and Viskens, A-S and Bonne, E and Borgers, E and Cox, C and De Vos, G and Derycke, L and Eeckels, A-S and Halewyck, S and Hox, V and Janssen, P and Janssen, P and Lemmens, W and Rogister, F and Speleman, K and Syssauw, M and Vanderveken, O and Vandewalle, E and Vanhee, S and Verhaeghe, B and Vroegop, A V and Van Zele, T and Gevaert, P and Hellings, P W},
  title = {Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study},
  journal = {Rhinology Journal},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {0--0},
  doi = {10.4193/rhin26.004}
}
Kostenlos starten →